Certara (NASDAQ:CERT) Hits New 1-Year Low – Time to Sell?

Certara, Inc. (NASDAQ:CERT)’s share price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $6.44 and last traded at $6.5880, with a volume of 172340 shares changing hands. The stock had previously closed at $6.51.

Analysts Set New Price Targets

CERT has been the topic of a number of research analyst reports. KeyCorp decreased their price target on shares of Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, January 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Morgan Stanley cut their price objective on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, December 18th. Rothschild & Co Redburn set a $10.00 target price on Certara in a report on Friday, November 21st. Finally, Barclays dropped their target price on shares of Certara from $14.00 to $13.00 and set an “overweight” rating for the company in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.82.

Certara Stock Up 1.2%

The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of 94.07 and a beta of 1.47. The firm has a 50-day moving average of $8.71 and a 200 day moving average of $10.09. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CERT. Wasatch Advisors LP increased its position in shares of Certara by 28.6% during the third quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock worth $212,608,000 after acquiring an additional 3,865,455 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Certara by 0.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 8,387,484 shares of the company’s stock valued at $73,894,000 after purchasing an additional 35,203 shares in the last quarter. Deerfield Management Company L.P. grew its stake in Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock valued at $82,357,000 after purchasing an additional 2,813,438 shares in the last quarter. Geneva Capital Management LLC increased its holdings in Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 6,160,754 shares of the company’s stock worth $75,284,000 after purchasing an additional 45,859 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its position in shares of Certara by 25.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock valued at $66,391,000 after purchasing an additional 1,145,554 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.